These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 8127868

  • 1. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T, Pinski J, Radulovic S, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Mar 01; 91(5):1701-5. PubMed ID: 8127868
    [Abstract] [Full Text] [Related]

  • 2. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T, Kitroser H, Levy J, Schally AV, Sharoni Y.
    Proc Natl Acad Sci U S A; 1992 Mar 15; 89(6):2336-9. PubMed ID: 1312718
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
    Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Jul 19; 91(15):7090-4. PubMed ID: 7518926
    [Abstract] [Full Text] [Related]

  • 4. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G, Schally AV, Kahan Z.
    Int J Oncol; 2000 Aug 19; 17(2):367-73. PubMed ID: 10891548
    [Abstract] [Full Text] [Related]

  • 5. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV.
    Cancer Res; 1993 Nov 15; 53(22):5439-46. PubMed ID: 8221683
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
    Milovanovic SR, Radulovic S, Schally AV.
    Breast Cancer Res Treat; 1992 Nov 15; 24(2):147-58. PubMed ID: 8443402
    [Abstract] [Full Text] [Related]

  • 7. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Int J Cancer; 1994 Oct 01; 59(1):51-5. PubMed ID: 7927904
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.
    Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV.
    Proc Natl Acad Sci U S A; 1989 Mar 01; 86(5):1648-51. PubMed ID: 2646641
    [Abstract] [Full Text] [Related]

  • 9. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV.
    Pancreas; 1993 Jan 01; 8(1):88-97. PubMed ID: 8093555
    [Abstract] [Full Text] [Related]

  • 10. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G, Szende B, Redding TW, Groot K, Schally AV.
    Proc Soc Exp Biol Med; 1989 Dec 01; 192(3):209-18. PubMed ID: 2574866
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1983 Mar 01; 80(5):1459-62. PubMed ID: 6219395
    [Abstract] [Full Text] [Related]

  • 12. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT.
    Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223
    [Abstract] [Full Text] [Related]

  • 13. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
    Srkalovic G, Wittliff JL, Schally AV.
    Cancer Res; 1990 Mar 15; 50(6):1841-6. PubMed ID: 2155060
    [Abstract] [Full Text] [Related]

  • 14. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
    Srkalovic G, Schally AV, Wittliff JL, Day TG, Jenison EL.
    Int J Oncol; 1998 Mar 15; 12(3):489-98. PubMed ID: 9472084
    [Abstract] [Full Text] [Related]

  • 15. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
    Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally AV.
    Endocrinology; 1990 Dec 15; 127(6):3052-60. PubMed ID: 2174343
    [Abstract] [Full Text] [Related]

  • 16. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P.
    J Natl Cancer Inst; 1997 Dec 03; 89(23):1803-9. PubMed ID: 9392622
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
    Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV.
    Breast Cancer Res Treat; 1992 Dec 03; 21(1):35-45. PubMed ID: 1391973
    [Abstract] [Full Text] [Related]

  • 18. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.
    Ayalon D, Farhi Y, Comaru-Schally AM, Schally AV, Eckstein N, Vagman I, Limor R.
    Neuroendocrinology; 1993 Aug 03; 58(2):153-9. PubMed ID: 8264861
    [Abstract] [Full Text] [Related]

  • 19. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV.
    J Clin Endocrinol Metab; 1993 Dec 03; 77(6):1458-64. PubMed ID: 8263128
    [Abstract] [Full Text] [Related]

  • 20. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
    Szende B, Srkalovic G, Groot K, Lapis K, Schally AV.
    Cancer Res; 1990 Jun 15; 50(12):3716-21. PubMed ID: 2160323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.